安比西林Ampicillin sodium | CAS# 69-52-3 APExBIO 貨號A2510
| 代理廠牌： |  |
| 原廠連結： | |
| 相關下載： |
特點
β-內醯胺類抗生素系列商品->>安比西林Ampicillin sodium
APExBIO Technology LLC 是一家領先的小分子抑制劑 (Small Molecule Inhibitors)/活化劑(Activators)、化合物庫( Compound Libraries)、胜肽(Peptides)、檢測試劑盒(Assay Kits)、螢光標記(Fluorescent Label)、酶(Enzymes)、修飾核苷酸(Modified Nucleotides)、mRNA 合成以及各種分子生物學工具的供應商。APExBIO提供廣泛的產品線，涵蓋 20 多個不同的研究領域，例如癌症(cancer)、免疫學(immunology)、神經科學(neurosciences)、細胞凋亡(apoptosis)和表觀遺傳學(epigenetics)等。公司總部位於美國德州休士頓USA (Houston, Texas)，致力於服務全球客戶。高度重視產品品質。所有產品均遵循嚴格的生產指南，並附有分析證書、HPLC、質譜(Mass Spectrum)和HMNR以及體外驗證(in vitro validation)。 APExBIO產品已被《Nature》、《Cell》和《Science》等眾多頂級同行評審期刊引用。>>更多APExBio商品
安比西林Ampicillin sodium | CAS# 69-52-3 APExBIO 貨號A2510
Ampicillin sodium is a competitive inhibitor of the enzyme transpeptidase with IC50 value of 1.8 μg/ml [1].
安比西林(Ampicillin)是一種酶轉肽酶的競爭性抑制劑，IC50 值為 1.8 μg/ml [1]。
安比西林(Ampicillin)是一種β-內醯胺類抗生素(β-lactam antibiotic)，通過抑制轉肽酶反應(transpeptidase reactions)來殺死細菌。轉肽酶(Transpeptidase)參與細胞壁生物合成(cell wall biosynthesis)的最後階段，對其的抑制最終導致細胞裂解(cell lysis) [1]。在乙醚處理的大腸桿菌146細胞中，安比西林(Ampicillin)在低於0.5 μg/ml的濃度下對轉肽酶反應(transpeptidase reaction)沒有明顯的抑制作用，但在1.8 μg/ml的濃度下表現出50%的抑制作用。在大腸桿菌 146 細胞中，安比西林(Ampicillin)的最低抑菌濃度 (MIC) 為 3.1 μg/ml [1]。在大腸桿菌(E. coli)和傷寒沙門氏菌中，濃度接近 MIC 值的安比西林(Ampicillin)和 Epicillin 殺死細菌的速度比阿莫西林慢 [2]。在實驗性小鼠感染中，以 0.2 ml/20 g 的劑量口服或皮下注射安比西林(Ampicillin)對大多數感染的治療效果明顯優於 Epicillin 和 Amoxycillin [2]。
| Storage | Store at -20°C |
| M.Wt | 371.4 |
| Cas No. | 69-52-3 |
| Formula | C16H18N3NaO4S |
| Solubility | ≥18.57 mg/mL in H2O; ≥73.6 mg/mL in DMSO; ≥75.2 mg/mL in EtOH |
| Chemical Name | sodium;(2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate |
| SDF | Download SDF |
| Canonical SMILES | CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)N)C(=O)[O-])C.[Na+] |
| Shipping Condition | Ship with blue ice, or upon other requests. |
| General tips | For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. We do not recommend long-term storage for the solution, please use it up soon. |
APExBIO台灣代理商: https://www.apexbt.com/
APExBIO提供優質的胜肽和生物分析試劑，廣泛產品線如Protease、Chromatin/Epigenetics表觀遺傳學、MAPK Signal、DNA Damege/DNA repair、細胞凋亡、腫瘤生物學、Stem cell等研究領域， 還提供定制的服務，包括多肽合成，抗體的生產和檢測的發展。產品線DNA/RNA prep kit、Drug Screening panel、Bioactive peptides、Growth factors、Biotinylation Reagents、tag peptides、amino Acids、Growth factors等。APExBIO產品質量都伴隨著證書的分析，高效液相色譜，質譜，和HMNR數據。
| Cat# | Product Name |
| A8743 | SYBR Safe DNA Gel Stain |
| A6001 | 3X (DYKDDDDK) Peptide |
| K1018 | Cell Counting Kit-8 (CCK-8) |
| A1902 | Z-VAD-FMK |
| A3008 | Y-27632 dihydrochloride |
| A6002 | DYKDDDDK tag Peptide |
| B8362 | 2’3′-cGAMP (sodium salt) |
| F4002 | Phos binding reagent (Phosbind) acrylamide |
| A8011 | Biotin-tyramide |
| A2585 | MG-132 |
| F4005 | Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa) |
| B1274 | AP20187 |
| K1007 | Protease Inhibitor Cocktail(EDTA-Free,100X in DMSO) |
| B8226 | InstaBlue Protein Stain Solution |
| A3011 | CHIR-99021 (CT99021) |
| A3007 | ABT-263 (Navitoclax) |
| B1524 | Erastin |
| B6055 | TCEP hydrochloride |
| K1031 | Phusion high-fidelity DNA polymerase |
| B1387 | (-)-Blebbistatin |
| B4664 | T-5224 |
| A8183 | Trichostatin A (TSA) |
| B3699 | ISRIB (trans-isomer) |
| A1910 | Bromodomain Inhibitor, (+)-JQ1 |
| B1293 | Y-27632 |
| A8167 | Rapamycin (Sirolimus) |
| A7024 | HOAt |
| A7025 | HOBt (anhydrous) |
| A8331 | Bleomycin Sulfate |
| A4333 | CPI-613 |
| K1070 | 2X SYBR Green qPCR Master Mix |
| A8005 | Sulfo-NHS-SS-Biotin |
| B4653 | BV6 |
| B5965 | Tamoxifen |
| A1901 | Q-VD-OPh hydrate |
| A8950 | UM 171 |
| K1046 | RNase Inhibitor, Murine |
| A3317 | Clozapine N-oxide (CNO) |
| A2614 | Bortezomib (PS-341) |
| A8003 | Sulfo-NHS-LC-Biotin |
| A4154 | Olaparib (AZD2281, Ku-0059436) |
| A8012 | Biotin-XX Tyramide Reagent |
| K1101 | PreScission Protease (PSP) |
| A8627 | Bafilomycin A1 |
| A8001 | Sulfo-NHS-Biotin |
| A3017 | Dasatinib (BMS-354825) |
| A2576 | E-64 |
| K1051 | Cy3 TSA Fluorescence System Kit |
| K1034 | 2X Taq PCR Master Mix (with dye) |
| B7972 | Pseudo-UTP |
| A8173 | Romidepsin (FK228, depsipeptide) |
| A4219 | Birinapant (TL32711) |
| A4371 | Ferrostatin-1 (Fer-1) |
| A8200 | DAPT (GSI-IX) |
| A8249 | SB 431542 |
| K1008 | Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) |
| A3133 | A 83-01 |
| A8192 | Staurosporine |
| B1054 | Resiquimod (R-848) |
| A3018 | Trametinib (GSK1120212) |
| A8184 | AICAR |
| K1025 | Direct Mouse Genotyping Kit |
| A2606 | Epoxomicin |
| A6006 | Hexa His tag peptide |
| A4393 | Paclitaxel (Taxol) |
| A8315 | NU7441 (KU-57788) |
| A4213 | Necrostatin-1 |
| A8885 | Ro 3306 |
| L1021 | DiscoveryProbe™ FDA-approved Drug Library |
| B1464 | KPT-330 |
| A8815 | SM-164 |
| B4879 | Blasticidin S HCl |
| A8793 | N3-kethoxal |
| K1047 | HyperScribe™ T7 High Yield RNA Synthesis Kit |
| A6004 | Influenza Hemagglutinin (HA) Peptide |
| B1036 | MLN4924 |
| A8178 | Panobinostat (LBH589) |
| A3963 | A-769662 |
| A3847 | SU5416 |
| B3252 | Dorsomorphin (Compound C) |
| B4758 | BAPTA-AM |
| A2513 | Geneticin, G-418 Sulfate |
| B6004 | PX-478 2HCl |
| A8955 | Z-YVAD-FMK |
| A8193 | ABT-737 |
| B2083 | Caspofungin Acetate |
| A8002 | NHS-Biotin |
| A8337 | CX-5461 |
| A8312 | Torin 1 |
| A2570 | Leupeptin, Microbial |
| K2170 | Alanine Aminotransferase (ALT or SGPT) Activity Colorimetric/Fluorometric Assay Kit |
| A4381 | FK866 (APO866) |
| B2143 | Tacrolimus (FK506) |
| A2571 | Pepstatin A |
| k1072 | First-Strand cDNA Synthesis Kit |
| A3003 | MDV3100 (Enzalutamide) |
| B5997 | Dyngo-4a |
| A3742 | Pyridostatin |
APExBIO提供優質的胜肽和生物分析試劑，廣泛產品線如Protease、Chromatin/Epigenetics表觀遺傳學、MAPK Signal、DNA Damege/DNA repair、細胞凋亡、腫瘤生物學、Stem cell等研究領域， 還提供定制的服務，包括多肽合成，抗體的生產和檢測的發展。產品線DNA/RNA prep kit、Drug Screening panel、Bioactive peptides、Growth factors、Biotinylation Reagents、tag peptides、amino Acids、Growth factors等。APExBIO產品質量都伴隨著證書的分析，高效液相色譜，質譜，和HMNR數據。
| A3477 | HOKU-81 | 58020-43-2 | 98.00% | Bronchodilators,metabolite of tulobuterol |
| A3478 | Hydroxyfasudil | 105628-72-6 | 98.00% | Rho-kinase inhibitor and vasodilator |
| A3479 | Hydroxyfasudil hydrochloride | 155558-32-0 | 98.71% | Rho-kinase inhibitor and vasodilator |
| A3481 | Ibutamoren Mesylate | 159752-10-0 | 98.00% | Growth hormone (GH) secretagogue |
| A3482 | Icotinib Hydrochloride | 1204313-51-8 | 98.00% | EGFR inhibitor,potent and specific |
| A3483 | IDO inhibitor 1 | 1204669-37-3 | 99.83% | Indoleamine-2,3-dioxygenase inhibitor |
| A3484 | Iguratimod | 123663-49-0 | 98.00% | COX-2 inhibitor,inhibits IL-1,IL-6,IL-8 and tumour necrosis factor. |
| A3485 | IKK-2 inhibitor VIII | 406209-26-5 | 98.00% | IKK-2 inhibitor,potent and selective |
| A3486 | IKK-3 Inhibitor | 862812-98-4 | 98.00% | IKK-3 Inhibitor |
| A3487 | Imatinib hydrochloride | 862366-25-4 | 98.00% | V-Abl/c-Kit/PDGFR inhibitor |
| A3492 | INCB 3284 dimesylate | 887401-93-6 | 98.00% | HCCR2 antagonist |
| A3493 | INCB024360 analogue | 914471-09-3 | 99.81% | potent and selective inhibitor of IDO1 |
| A3494 | INCB3344 | 1262238-11-8 | 98.01% | CCR2 chemokine receptor antagonist |
| A3495 | INCB8761(PF-4136309) | 1341224-83-6 | 98.00% | CCR2 Antagonist,potent and selective |
| A3496 | Indacaterol | 312753-06-3 | 98.00% | β2-agonist |
| A3498 | Inolitazone | 223132-37-4 | 98.00% | PPARgamma agonist |
| A3499 | Inolitazone dihydrochloride | 223132-38-5 | 98.00% | PPARγ agonist,high-affinity and novel |
| A3500 | IRAK inhibitor 1 | 1042224-63-4 | 98.11% | IRAK-4 inhibitor |
| A3501 | IRAK inhibitor 2 | 928333-30-6 | 98.00% | IRAK inhibitor |
| A3502 | IRAK inhibitor 3 | 1012343-93-9 | 98.00% | IRAK inhibitor |
| A3503 | IRAK inhibitor 4 | 1012104-68-5 | 98.00% | IRAK inhibitor |
| A3504 | IRAK inhibitor 6 | 1042672-97-8 | 99.90% | IRAK-4 inhibitor |
| A3505 | IRAK-1-4 Inhibitor I | 509093-47-4 | 98.17% | IRAK-1/4 inhibitor |
| A3506 | Isobavachalcone | 20784-50-3 | 98.00% | Diverse biological activity compound |
| A3507 | Istaroxime | 203737-93-3 | 98.00% | Na+/K+ ATPase inhibitor |
| A3508 | Istaroxime hydrochloride | 374559-48-5 | 98.00% | Inhibitor of Na+/K+ ATPase |
| A3510 | Ivacaftor benzenesulfonate | 1134822-09-5 | 99.90% | CFTR Potentiator |
| A3511 | Ivacaftor hydrate | 1134822-07-3 | 98.00% | CFTR Potentiator |
| A3512 | IWP-2 | 686770-61-6 | 98.00% | Wnt production inhibitor,PORCN inhibitor |
| A3513 | Ixabepilone | 219989-84-1 | 98.00% | Epothilone B analog;microtubule-stabilizing agent |
| A3515 | JANEX-1 | 202475-60-3 | 99.27% | JAK3 inhibitor |
| A3516 | JC-1 | 3520-43-2 | 98.00% | Probe for Mitochondrial Membrane Potential |
| A3517 | JDTic | 361444-66-8 | 98.00% | Opioid antagonist |
| A3518 | JDTic 2HCl | 785835-79-2 | 98.00% | κ-opioid receptor antagonist |
| A3519 | JNK-IN-7 | 1408064-71-0 | 98.13% | Selective JNK inhibitor |
| A3520 | JNK-IN-8 | 1410880-22-6 | 99.45% | JNK inhibitor, selective and irreversible |
| A3522 | Kaempferide | 491-54-3 | 99.53% | O-methylated flavonol |
| A3524 | kb NB 142-70 | 1233533-04-4 | 98.21% | Inhibitor of protein kinase D,selective |
| A3525 | KB-R7943 mesylate | 182004-65-5 | 98.75% | Inhibitor of the reverse mode of the Na+/Ca2+ exchanger |
| A3526 | Ketone Ester | 1208313-97-6 | 98.00% | Delaies CNS-OT seizures in rats |
| A3527 | Ki20227 | 623142-96-1 | 98.43% | C-Fms tyrosine kinase inhibitor |
| A3528 | Kinetin | 525-79-1 | 99.89% | Plant growth hormones |
| A3529 | KN-92 | 176708-42-2 | 99.55% | CaMKII inhibitor |
| A3530 | KN-92 hydrochloride | 1431698-47-3 | 99.89% | Inactive derivative of KN-93,control compound |
| A3531 | KN-92 phosphate | 1135280-28-2 | 99.35% | CaMKII inhibitor |
| A3532 | KN-93 | 139298-40-1 | 99.83% | CaMKII inhibitor,selective and cometitive |
| A3533 | Ko 143 | 461054-93-3 | 98.00% | BCRP inhibitor,potent and selective |
| A3534 | KU14R | 189224-48-4 | 98.00% | I(3)-R antagonist |
| A3535 | KX2-391 dihydrochloride | 1038395-65-1 | 98.00% | Src kinase inhibitor |
| A3536 | L-165041 | 79558-09-1 | 98.30% | PPARβ/δ agonist,cell permeable,potent and selective |
| A3538 | Laropiprant | 571170-77-9 | 98.00% | DP1 receptor antagonist,potent and selective |
| A3539 | Lck Inhibitor | 847950-09-8 | 98.00% | Lck inhibitor |
| A3541 | LCL161 | 1005342-46-0 | 99.81% | Antagonist of IAPs inhibitor |
| A3542 | LCQ-908 | 956136-95-1 | 98.00% | DGAT1 inhibitor |
| A3543 | LDE225 Diphosphate | 1218778-77-8 | 99.83% | Smo antagonist |
| A3544 | LDK378 dihydrochloride | 1380575-43-8 | 99.93% | ALK inhibitor |
| A3545 | LDN193189 Hydrochloride | 1062368-62-0 | 98.76% | ALK inhibitor,potent and selective |
| A3548 | Lersivirine | 473921-12-9 | 98.00% | NNRT inhibitor |
| A3549 | Lesinurad | 878672-00-5 | 99.77% | URAT1 inhibitor |
| A3550 | Letermovir | 917389-32-3 | 99.52% | Novel anti-CMV compound |
| A3551 | Leuprolide Acetate | 74381-53-6 | 99.74% | Pituitary GnRH receptors agonist |
| A3552 | Levomefolate calcium | 151533-22-1 | 99.44% | Artificial form of folate |
| A3555 | Limonin | 1180-71-8 | 99.76% | Carcinogenesis inhibitor and HIV-1 replication inhibitor |
| A3556 | LKB1 (AAK1 dual inhibitor) | 1093222-27-5 | 99.04% | Pim-1 kinase inhibitor |
| A3558 | LRRK2-IN-1 | 1234480-84-2 | 99.18% | LRRK2 inhibitor,cell-permeable and ATP competitive |
| A3561 | Lu AE58054 Hydrochloride | 467458-02-2 | 99.32% | 5-HT(6)R antagonist |
| A3562 | Lucidin | 478-08-0 | 98.00% | Natural component of Rubia tinctorum L |
| A3563 | LUF6000 | 890087-21-5 | 98.00% | A3 AR modulator |
| A3564 | Luliconazole | 187164-19-8 | 99.20% | Azole antifungal agent(interdigital tinea pedis) |
| A3565 | LX-1031 | 945976-76-1 | 99.50% | TPH inhibitor |
| A3566 | LX1606 | 1137608-69-5 | 98.00% | Tryptophan hydroxylase (TPH) inhibitor |
| A3567 | LX-4211 | 1018899-04-1 | 99.67% | SGLT1/SGLT2 inhibitor |
| A3568 | LY 303511 | 154447-38-8 | 98.00% | MTOR inhibitor |
| A3569 | LY 344864 | 186544-26-3 | 98.00% | 5-HT1F receptor agonist,potent and selective |
| A3570 | LY2090314 | 603288-22-8 | 99.78% | Potent GSK-3 inhibitor |
| A3571 | LY2183240 | 874902-19-9 | 98.00% | Blocker of anandamide uptake,highly potent |
| A3573 | LY2801653 | 1206799-15-6 | 99.47% | MET inhibitor |
| A3575 | LY2835219 free base | 1231929-97-7 | 99.42% | CDK inhibitor |
| A3576 | LY2874455 | 1254473-64-7 | 98.94% | FGF/FGFR Inhibitor |
| A3577 | LY341495 | 201943-63-7 | 98.00% | Metabotropic glutamate receptor antagonist |
| A3583 | Matrine | 519-02-8 | 98.87% | Alkaloid found in Sophora plant |
| A3584 | Maxacalcitol | 103909-75-7 | 98.00% | Non-calcemic vitamin D3 analog and VDR ligand. |
| A3586 | MB05032 | 261365-11-1 | 98.00% | GNG inhibitor,special and efficacious |
| A3587 | MBX-2982 | 1037792-44-1 | 98.00% | GPR119 agonist,selective and orally-available |
| A3588 | MC 1046 | 126860-83-1 | 98.00% | Vitamin D3 analog |
| A3592 | Medetomidine | 86347-14-0 | 98.00% | α2-adrenoceptor agonist |
| A3593 | Mefloquine hydrochloride | 51773-92-3 | 99.86% | Quinoline methanol antimalarial agent, |
| A3594 | MEK inhibitor | 334951-92-7 | 98.00% | Potent MEK inhibitor, Antitumor agent |
| A3599 | Metoclopramide | 364-62-5 | 99.94% | Dopamine receptor antagonist |
| A3600 | MF63 | 892549-43-8 | 98.00% | MPGES-1 inhibitor |
| A3601 | mGlu2 agonist | 1311385-32-6 | 98.00% | Anti-depressants,novel potent agent |
| A3602 | MI-2 | 1271738-62-5 | 99.65% | Menin-MLL Inhibitor |
| A3603 | MI-3 | 1271738-59-0 | 98.00% | Menin-MLL Inhibitor |
| A3604 | Mibefradil | 116644-53-2 | 98.07% | Calcium channel blocker |
| A3605 | Mibefradil dihydrochloride | 116666-63-8 | 98.00% | Ca2+ channel blocker ,antihypertensive |
| A3606 | Micafungin sodium | 208538-73-2 | 99.56% | Inhibitor of β-(1,3)-D-glucan synthesis;fungicide |
| A3608 | MK 0893 | 870823-12-4 | 98.58% | Glucagon receptor/IGF-1R antagonist |
| A3609 | MK-0591 | 136668-42-3 | 98.00% | FLAP inhibitor,potent and selective |
| A3611 | MK-0812 | 624733-88-6 | 98.00% | antagonist of chemokine receptor CCR-2 |
| A3612 | MK-0974 | 781649-09-0 | 98.00% | CGRP receptor antagonist |
| A3613 | MK-2894 | 1006036-87-8 | 98.00% | EP4 receptor inhibitor |
| A3615 | MK-3207 | 957118-49-9 | 98.00% | CGRP receptor antagonist |
| A3617 | MK-4827 | 1038915-60-4 | 98.93% | PARP-1/-2 inhibitor,potent and selective |
| A3618 | MK-5172 | 1350514-68-9 | 99.79% | HCV NS3/4a protease inhibitor |
| A3619 | MK-5172 hydrate | 1350462-55-3 | 98.00% | HCV NS3/4a protease inhibitor |
| A3620 | MK-5172 potassium salt | 1206524-86-8 | 98.00% | HCV NS3/4a protease inhibitor |
| A3621 | MK-5172 sodium salt | 1425038-27-2 | 98.00% | HCV NS3/4a protease inhibitor |
| A3623 | MK-6892 | 917910-45-3 | 99.65% | Highly potential GPR109A agonist |
| A3624 | MK-8033 | 1001917-37-8 | 98.00% | C-MET inhibitor |
| A3626 | ML-7 hydrochloride | 110448-33-4 | 98.43% | Myosin light chain kinase inhibitor |
| A3627 | MLN 2480 | 1096708-71-2 | 98.99% | Pan-Raf kinase inhibitor,investigational |
| A3628 | MLN120B | 783348-36-7 | 99.82% | IκB Kinase β Inhibitor |
| A3629 | MLN4924 HCl salt | 1160295-21-5 | 98.00% | NAE inhibitor |
| A3630 | MMAD | 203849-91-6 | 98.00% | Tubulin inhibitor,highly potent |
| A3631 | Monomethyl auristatin E | 474645-27-7 | 98.34% | Antimitotic agent |
| A3632 | Motesanib | 453562-69-1 | 98.00% | Inhibitor of Flk-1/Flt-4/PDGFR-/c-Kit |
| A3633 | MPEP Hydrochloride | 219911-35-0 | 98.00% | MGlu5 receptor antagonist |
| A3634 | MPTP hydrochloride | 23007-85-4 | 99.79% | Dopaminergic neurotoxin,induced reduction in the DOPAC HVA/dopamine (DA) ratio |
| A3636 | MTEP hydrochloride | 1186195-60-7 | 98.00% | MGlu5 antagonist |
| A3637 | GDC-mTOR inhibitor | 1207358-59-5 | 98.00% | MTOR inhibitor |
| A3641 | Naphthoquine phosphate | 173531-58-3 | 98.00% | Antimalarial drug |
| A3642 | Narciclasine | 29477-83-6 | 98.00% | Modulates the Rho/ROCK/LIM kinase/cofilin pathway |
| A3643 | Narlaprevir | 865466-24-6 | 98.00% | HCV NS3 protease inhibitor |
| A3645 | NB-598 | 131060-14-5 | 99.35% | SE inhibitor |
| A3646 | NB-598 hydrochloride | 136719-25-0 | 98.00% | SE inhibitor |
| A3647 | NB-598 Maleate | 155294-62-5 | 98.97% | Squalene epoxidase inhibitor |
| A3649 | NBD-556 | 333353-44-9 | 98.00% | HIV-1 entry inhibitor,CD4 mimetic,block gp120-CD4 interaction |
| A3652 | Necrostatin 2 | 852391-19-6 | 98.00% | In vitro necroptosis inhibitor |
| A3653 | Nelfinavir Mesylate | 159989-65-8 | 98.04% | HIV protease inhibitor,antiretroviral drug for HIV treatment |
| A3655 | Nesbuvir | 691852-58-1 | 99.79% | NS5B polymerase inhibitor |
| A3658 | NG25 | 1315355-93-1 | 98.00% | TAK1 inhibitor |
| A3659 | Nifuratel | 4936-47-4 | 98.00% | Antibacterial, antifungal, and antiprotozoal compound |
| A3660 | Nilotinib monohydrochloride monohydrate | 923288-90-8 | 99.89% | Bcr-Abl inhibitor |
| A3662 | NNC 55-0396 | 357400-13-6 | 98.00% | T-type calcium channel blocker |
| A3663 | Noopept | 157115-85-0 | 98.00% | Nootropic and neuroprotective agent |
| A3664 | Nordihydroguaiaretic acid | 500-38-9 | 99.83% | Anti-tumor agent;lipoxygenase inhibitor |
| A3665 | Nortadalafil | 171596-36-4 | 98.00% | PDE5 inhibitor |
| A3666 | NP118809 | 41332-24-5 | 98.00% | N-type calcium channel blocker |
| A3667 | NPS-2143 hydrochloride | 324523-20-8 | 99.89% | Calcium ion-sensing receptor antagonist |
| A3668 | NS309 | 18711-16-5 | 98.00% | Calcium-Activated Potassium Channel activator |
| A3670 | Nucleozin | 341001-38-5 | 99.55% | Targets influenza A nucleoprotein (NP),cell-permeable isoxazolylpiperazine compound |
| A3671 | Nutlin-3a chiral | 675576-98-4 | 98.39% | MDM2 inhibitor, antiproliferative and antiproapoptotic |
| A3672 | NVP-BAG956 | 853910-02-8 | 98.00% | PI3K and PDK1 inhibitor |
| A3673 | NVP-BGJ398 phosphate | 1310746-10-1 | 99.78% | FGFR inhibitor |
| A3674 | NVP-BKM120 Hydrochloride | 1312445-63-8 | 98.02% | PI3K inhibitor |
| A3675 | NVP-BSK805 | 1092499-93-8 | 98.00% | ATP-competitive JAK2 inhibitor |
| A3676 | NVP-LCQ195 | 902156-99-4 | 97.50% | CDK1/CDK2/CDK5 inhibitor |
| A3680 | Olcegepant | 204697-65-4 | 97.46% | Non-peptide receptor of CGRP,first potent and selective |
| A3681 | Olmesartan | 144689-24-7 | 99.20% | Angiotensin II receptor antagonist |
| A3683 | Olprinone Hydrochloride | 119615-63-3 | 99.74% | Phosphodiesterase 3 (PDE3) inhibitor, selective |
| A3684 | ONO-AE3-208 | 402473-54-5 | 97.73% | EP4 receptor antagonist,high affinity and selective |
| A3686 | Orteronel | 566939-85-3 | 98.00% | For castration-resistant prostate cancer, clinical candidate |
| A3688 | Oseltamivir | 196618-13-0 | 96.83% | inhibitor of influenza neuraminidase |
| A3689 | Oseltamivir acid | 187227-45-8 | 99.08% | Influenza neuraminidase inhibitor |
| A3690 | Otamixaban | 193153-04-7 | 98.00% | Direct factor Xa inhibitors,potent and selective |
| A3691 | Otenabant | 686344-29-6 | 98.00% | CB1 receptor antagonist |
| A3692 | OTX-015 | 202590-98-5 | 99.57% | BRD inhibitor |
| A3695 | Pafuramidine | 186953-56-0 | 98.00% | Prodrug of furamidine |
| A3696 | Palifosfamide | 31645-39-3 | 98.00% | Active metabolite of ifosfamide (IFOS) |
| A3697 | Palonosetron | 135729-61-2 | 98.00% | 5-HT3 antagonist |
| A3700 | Paradol | 27113-22-0 | 98.00% | Active flavor constituent of the seeds of Guinea pepper |
| A3702 | Paricalcitol | 131918-61-1 | 98.00% | Analog of VD2 active form |
| A3704 | PD 123319 ditrifluoroacetate | 136676-91-0 | 99.14% | Angiotensin AT2 receptor antagonist |
| A3706 | PDK1 inhibitor | 1001409-50-2 | 98.00% | PDK1 inhibitor |
| A3707 | Pemetrexed disodium hemipenta hydrate | 357166-30-4 | 99.94% | Antifolate and antimetabolite agent |
| A3708 | Pentostatin | 53910-25-1 | 99.05% | Irreversible adenosine deaminase inhibitor |
| A3709 | Peramivir | 330600-85-6 | 99.01% | Aeuraminidase inhibitor;antiviral drug |
| A3711 | PF-03084014 | 865773-15-5 | 98.52% | γ-secretase inhibitor |
| A3712 | PF-04217903 methanesulfonate | 956906-93-7 | 98.00% | C-Met inhibitor,selective and ATP-competitive |
| A3715 | PF-04971729 | 1210344-57-2 | 98.00% | SGLT inhibitor |
| A3716 | PF-3758309 | 898044-15-0 | 98.39% | PAK4 inhibitor |
| A3717 | PF-543 | 1415562-82-1 | 99.32% | SphK1 inhibitor,cell-permeate,potent and selective |
| A3718 | PF-543 Citrate | 1415562-83-2 | 98.95% | SphK1 inhibitor,potent and cell-permeate |
| A3719 | PF-670462 | 950912-80-8 | 99.66% | CK1 ε/δ inhibitor |
| A3720 | PF-8380 | 1144035-53-9 | 98.23% | Autotaxin inhibitor,potent and specific |
| A3721 | PHA-767491 | 845714-00-3 | 99.03% | Cdc7/cdk9 inhibitor, potent, ATP-competitive |
| A3722 | Phenylpiracetam | 77472-70-9 | 99.21% | Nootropic derivative of piracetam |
| A3723 | Phloretin | 60-82-2 | 99.12% | A dihydrochalcone found in apple |
| A3724 | PI-103 Hydrochloride | 371935-79-4 | 98.00% | DNA-PK/PI 3-kinase/mTOR inhibitor |
| A3727 | Pitolisant hydrochloride | 903576-44-3 | 99.71% | Nonimidazole inverse agonist |
| A3729 | PJ34 | 344458-19-1 | 95.69% | PARP-l inhibitor |
| A3730 | PND-1186 | 1061353-68-1 | 99.75% | Potent FAK inhibitor |
| A3732 | Poloxin | 321688-88-4 | 98.00% | PLK1 inhibitor |
| A3733 | Pramipexole dihydrochloride | 104632-25-9 | 98.94% | Dopamine receptor agonist |
| A3735 | Preladenant | 377727-87-2 | 98.00% | Adenosine A2A receptor antagonist |
| A3736 | PRT062607 Hydrochloride | 1370261-97-4 | 98.63% | SYK inhibitor,potent and selective |
| A3738 | PSI-7977 | 1190307-88-0 | 99.81% | Antiviral agents for chronic HCV infection |
| A3740 | Puromycin aminonucleoside | 58-60-6 | 98.19% | Aminonucleoside portion of the antibiotic puromycin |
| A3741 | Pyridone 6 | 457081-03-7 | 99.60% | Pan-JAK inhibitor |
| A3742 | Pyridostatin | 1085412-37-8 | 98.02% | Drug used for promoting growth arrest |
| A3744 | Quetiapine | 111974-69-7 | 98.00% | Dopamine receptor antagonist |
| A3746 | R1530 | 882531-87-5 | 98.00% | Antiangiogenesis,mitosis-angiogenesis inhibitor (MAI) |
| A3747 | R-7128 | 940908-79-2 | 98.00% | NS5B inhibitor |
| A3749 | Radezolid | 869884-78-6 | 99.32% | Novel oxazolidinone antibiotic agent |
| A3750 | Regorafenib hydrochloride | 835621-07-3 | 98.57% | Tyrosine kinase inhibitor |
| A3752 | Reparixin | 266359-83-5 | 98.11% | Inhibitor of CXCL8 receptor and CXCR1/CXCR2 activation |
| A3753 | Reparixin L-lysine salt | 266359-93-7 | 97.82% | CXCR1/CXCR2 inhibitor |
| A3754 | RepSox | 446859-33-2 | 99.83% | ALK5 inhibitor,potent and selective |
| A3755 | Resminostat hydrochloride | 1187075-34-8 | 98.00% | HDAC inhibitor |
| A3756 | Retaspimycin | 857402-23-4 | 98.00% | HSP90 inhibitor,antiproliferative and antineoplastic |
| A3758 | Retigabine dihydrochloride | 150812-13-8 | 99.27% | Antiepileptic compound |
| A3759 | Retinyl glucoside | 136778-12-6 | 98.00% | Metabolites of vitamin A |
| A3760 | Reversine | 656820-32-5 | 99.09% | A3 adenosine receptor antagonist,ARK-1/-2/-3 inhibitor |
| A3761 | RG2833 | 1215493-56-3 | 98.06% | Brain-penetrant HDAC inhibitor |
| A3762 | RG7112 | 939981-39-2 | 98.58% | MDM2 inhibitor, first clinical |
| A3763 | RG7388 | 1229705-06-9 | 99.82% | MDM2 antagonist, oral, selective |
| A3764 | RI-1 | 415713-60-9 | 99.54% | RAD51 inhibitor,cell-permeable |
| A3765 | Rilpivirine | 500287-72-9 | 99.64% | Inhibitor of next-generation nonnucleoside reverse transcriptase |
| A3766 | Rimonabant hydrochloride | 158681-13-1 | 98.01% | CB1 receptor inverse agonist |
| A3767 | Riociguat | 625115-55-1 | 99.77% | Soluble guanylate cyclase (sGC) stimulator |
| A3768 | Rivastigmine | 123441-03-2 | 99.68% | Cholinesterase inhibitor |
| A3770 | RJR-2403 oxalate | 220662-95-3 | 98.00% | Nicotinic receptor agonist |
| A3771 | RKI-1447 | 1342278-01-6 | 99.52% | Potent ROCK1/ROCK2 inhibitor |
| A3776 | Rotigotine | 99755-59-6 | 98.00% | Agonist of dopamine D2/D3 receptor |
| A3777 | Rotigotine hydrochloride | 125572-93-2 | 98.00% | Agonist of dopamine D2/D3 receptor |
| A3778 | RS 127445 | 199864-87-4 | 98.01% | 5-HT2B receptor antagonist,high affinity |
| A3780 | RU 58841 | 154992-24-2 | 98.40% | Androgen receptor antagonist |
| A3781 | Ruxolitinib phosphate | 1092939-17-7 | 98.75% | JAK1/JAK2 inhibitor |
| A3783 | S0859 | 1019331-10-2 | 98.00% | NBC inhibitor,potent and selective |
| A3784 | Safinamide | 133865-89-1 | 99.64% | MAO-B inhibitor |
| A3787 | Salirasib | 162520-00-5 | 99.28% | Inhibitor of active Ras protein |
| A3789 | Salmeterol xinafoate | 94749-08-3 | 98.11% | β2-adrenergic receptor agonist |
| A3790 | Saquinavir | 127779-20-8 | 98.00% | HIV Protease Inhibitor |
| A3791 | Saquinavir mesylate | 149845-06-7 | 99.75% | HIV Protease Inhibitor |
| A3792 | SB 239063 | 193551-21-2 | 98.63% | P38 MAP kinase inhibitor |
| A3794 | SB1317 | 937270-47-8 | 98.02% | CDK,JAK and FLT inhibitor |
| A3795 | SB-222200 | 174635-69-9 | 98.86% | Human NK-3 receptor antagonist |
| A3798 | SB-408124 Hydrochloride | 1431697-90-3 | 98.00% | OX1 receptor antagonist,selective and non-peptide |
| A3800 | SB-674042 | 483313-22-0 | 98.00% | OX1 selective antagonist |
| A3802 | SCH 527123 | 473727-83-2 | 99.40% | CXCR1 and CXCR2 receptors antagonist |
| A3804 | SCH-1473759 | 1094069-99-4 | 98.00% | Aurora A/B inhibitor |
| A3805 | SCH772984 | 942183-80-4 | 98.06% | ERK1 and ERK2 inhibitor |
| A3806 | SCH900776 S-isomer | 891494-64-7 | 99.18% | Checkpoint kinase(Chk)inhibitor |
| A3808 | SD-208 | 627536-09-8 | 99.11% | TGF-βR I kinase inhibitor |
| A3809 | SDZ 220-581 | 174575-17-8 | 98.00% | NMDA glutamate receptor subtype antagonist |
| A3811 | SEA0400 | 223104-29-8 | 99.20% | Specific inhibitor of Na+/Ca2+ exchange |
| A3814 | Seocalcitol | 134404-52-7 | 98.00% | Vitamin D receptor agonist |
| A3815 | Setiptiline | 57262-94-9 | 98.00% | Serotonin receptor antagonist |
| A3816 | Setiptiline maleate | 85650-57-3 | 98.00% | Serotonin receptor antagonist |
| A3818 | Silvestrol | 697235-38-4 | 98.00% | Antineoplastic |
| A3820 | Simeprevir | 923604-59-5 | 99.42% | Inhibitor of HCV NS3/4A protease |
| A3821 | SRT2104 (GSK2245840) | 1093403-33-8 | 98.50% | SIRT1 activator,selective |
| A3823 | SJB2-043 | 63388-44-3 | 99.78% | USP1 inhibitor |
| A3824 | Skepinone-L | 1221485-83-1 | 99.88% | P38-MAPK inhibitor,potent and selective |
| A3825 | SLx-2119 | 911417-87-3 | 98.80% | Selective ROCK2 inhibitor |
| A3826 | SMIP004 | 143360-00-3 | 98.17% | Apoptosis inducer |
| A3828 | Sobetirome | 211110-63-3 | 99.01% | Agonist of tyroid hormone receptor |
| A3829 | sodium 4-pentynoate | 101917-30-0 | 98.00% | chemical reporter for the profiling of acetylated proteins |
| A3832 | Solasodine | 126-17-0 | 98.00% | Neuroprotective antioxidant glycoalkaloid |
| A3834 | SQ109 | 502487-67-4 | 98.00% | Antibiotic for treatment of pulmonary TB |
| A3835 | SR1078 | 1246525-60-9 | 98.65% | Orphan receptor agonist |
| A3836 | SR3335 | 293753-05-6 | 99.52% | RORα agonist,partial inverse and selective |
| A3837 | DL-α-Hydroxyglutaric acid disodium salt | 40951-21-1 | 98.00% | alpha hydroxy acid |
| A3838 | SRT3109 | 1204707-71-0 | 98.00% | CXCR2 ligand |
| A3839 | SRT3190 | 1204707-73-2 | 99.56% | CXCR2 ligand,SIRT1 activator |
| A3840 | ST 2825 | 894787-30-5 | 98.00% | Inhibitor of MyD88 dimerization |
| A3843 | SU 5402 | 215543-92-3 | 98.48% | VEGFR2/FGFR/PDGFR/EGFR inhibitor |
| A3844 | SU14813 | 627908-92-3 | 98.00% | Tyrosine kinase inhibitor |
| A3846 | SU14813 maleate | 849643-15-8 | 98.00% | VEGFR/PDGFR/Kit/FLT-3 inhibitor |
| A3847 | SU5416 | 204005-46-9 | 99.06% | VEGF receptor inhibitor and AHR agonist |
| A3848 | Tacalcitol | 57333-96-7 | 98.00% | Promotes normal bone development by regulating calcium |
| A3850 | TAK-242 | 243984-11-4 | 99.53% | TLR 4 signaling inhibitor |
| A3853 | Talarozole | 201410-53-9 | 98.00% | Cytochrome P450 inhibitor |
| A3854 | Talnetant | 174636-32-9 | 98.00% | NK3 receptor antagonist,potent and selective |
| A3856 | Tamibarotene | 94497-51-5 | 98.41% | RARα agonist |
| A3857 | Tanaproget | 304853-42-7 | 98.00% | Progesterone receptor agonist |
| A3858 | Taranabant | 701977-09-5 | 98.00% | Cannabinoid receptor type 1 inverse agonist |
| A3859 | Tariquidar methanesulfonate, hydrate | 625375-83-9 | 99.49% | P-glycoprotein inhibitor, potent and selective |
| A3860 | Tasquinimod | 254964-60-8 | 99.47% | Antiangiogenic and antineoplastic agent |
| A3861 | TBB | 17374-26-4 | 99.23% | Casein kinase-2 (CK2) inhibitor |
| A3862 | TC-DAPK 6 | 315694-89-4 | 98.00% | DAPK inhibitor |
| A3863 | Tedizolid | 856866-72-3 | 99.63% | Oxazolidinone for gram-positive infections |
| A3864 | Tegobuvir | 1000787-75-6 | 98.97% | HCV RNA replication inhibitor |
| A3865 | Teneligliptin hydrobromide | 906093-29-6 | 99.90% | Dipeptidyl peptidase-4 inhibitor |
| A3870 | TG 100801 | 867331-82-6 | 98.00% | Multi-kinase inhibitor |
| A3872 | TH-302 | 918633-87-1 | 98.40% | Hypoxia-activated prodrug,inhibits H460/HT29 cell growth |
| A3873 | Tianeptine | 66981-73-5; 72797-41-2 | 99.46% | 5-HT facilitator |
| A3874 | Tiotropium Bromide | 136310-93-5 | 99.39% | MAChR M antagonist |
| A3875 | Tipiracil hydrochloride | 183204-72-0 | 99.74% | Thymidine phosphorylase inhibitor |
| A3876 | Tipranavir | 174484-41-4 | 98.00% | HIV protease inhibitor |
| A3877 | Tirofiban hydrochloride monohydrate | 150915-40-5 | 99.46% | Glycoprotein IIb/IIIa inhibitor |
| A3878 | TMC353121 | 857066-90-1 | 98.00% | Potent RSV fusion inhibitor |
| A3879 | Toceranib | 356068-94-5 | 98.00% | c-Kit/VEGFR/PDGFR inhibtor |
| A3881 | Toll-like receptor modulator | 926927-42-6 | 98.00% | TLR antagonist |
| A3883 | Tonabersat | 175013-84-0 | 98.00% | Gap junction modulator,novel benzopyran compound for Migraine and epilepsy treatment |
| A3884 | Toremifene | 89778-26-7 | 98.00% | Estrogen-receptor modulator |
| A3885 | Tozadenant | 870070-55-6 | 99.46% | Adenosine 2a receptor antagonist,novel and selective |
| A3886 | Trabectedin | 114899-77-3 | 98.00% | Antitumour agent |
| A3887 | Trametinib DMSO solvate | 1187431-43-1 | 98.64% | Allosteric MEK1/MEK2 kinase inhibitor |
| A3888 | Trelagliptin | 865759-25-7 | 99.66% | DPP-4 inhibitor,long-acting and selective |
| A3889 | Trelagliptin succinate | 1029877-94-8 | 98.00% | DPP-4 inhibitor |
| A3891 | Triptolide | 38748-32-2 | 99.16% | IL-2/MMP-3/MMP7/MMP19 inhibitor |
| A3892 | Triptonide | 38647-11-9 | 99.15% | dCTP Pyrophosphatase inhibitor |
| A3893 | Troglitazone | 97322-87-7 | 98.99% | Selective PPARγ agonist |
| A3894 | TTP 22 | 329907-28-0 | 98.33% | CK2 inhibitor |
| A3895 | TUG-770 | 1402601-82-4 | 99.46% | FFA1/GPR40 agonist |
| A3896 | Tulathromycin A | 217500-96-4 | 98.00% | Triamilide antimicrobial |
| A3899 | UK-5099 | 56396-35-1 | 99.41% | MCTs and MPC inhibitor |
| A3900 | Umeclidinium bromide | 869113-09-7 | 98.74% | MAChR antagonist |
| A3901 | UNC1215 | 1415800-43-9 | 98.55% | Chemical probe for the methyllysine (Kme) |
| A3902 | VAL-083 | 23261-20-3 | 98.00% | Bi-functional alkylating agent |
| A3903 | Valaciclovir | 124832-26-4 | 98.00% | Prodrug of aciclovir for herpes virus treatment |
| A3905 | Valspodar | 121584-18-7 | 96.32% | P-glycoprotein inhibitor |
| A3906 | Vandetanib hydrochloride | 524722-52-9 | 99.92% | VEGFR/EGFR inhibitor |
| A3909 | VCH-916 | 1200133-34-1 | 98.00% | HCV NS5B polymerase inhibitor |
| A3915 | Vernakalant Hydrochloride | 748810-28-8 | 98.00% | Ion channel blocker,investigational antiarrhythmic |
| A3918 | Vilazodone | 163521-12-8 | 99.06% | Combined SSRI and 5-HT1A receptor partial agonist |
| A3919 | Vilazodone Hydrochloride | 163521-08-2 | 98.38% | Combined SSRI and 5-HT1A receptor partial agonist |
| A3920 | Vinblastine sulfate | 143-67-9 | 99.06% | Anti-mitotic agent |
| A3921 | Vinorelbine ditartrate | 125317-39-7 | 99.06% | Anti-mitotic chemotherapy drug |
| A3923 | VO-Ohpic trihydrate | 476310-60-8 | 98.00% | PTEN inhibitor |
| A3924 | Voreloxin | 175414-77-4 | 98.00% | Topo II inhibitor |
| A3925 | Voreloxin Hydrochloride | 175519-16-1 | 98.00% | Antineoplastic naphthyridine analogue |
| A3926 | Vortioxetine | 508233-74-7 | 99.27% | 5-HT receptors antagonist |
| A3927 | VS-5584 (SB2343) | 1246560-33-7 | 99.94% | MTOR/P13K inhibitor,potent and selective |
| A3931 | VX-11e | 896720-20-0 | 98.99% | ERK inhibitor |
| A3932 | WAY 316606 | 915759-45-4 | 99.64% | sFRP-1 inhibitor |
| A3933 | WAY-100635 | 162760-96-5 | 99.64% | 5-HT1A receptor antagonist,potent and selective |
| A3935 | WEHI-539 | 1431866-33-9 | 99.23% | Bcl-xL inhibitor,potent and selective |
| A3936 | WHI-P97 | 211555-05-4 | 98.00% | Janus kinase (JAK)-3 inhibitor |
| A3937 | XL019 | 945755-56-6 | 97.66% | JAK2 inhibitor,potent and selective |
| A3939 | XL228 | 898280-07-4 | 99.32% | IGF1R/AURORA /FGFR1-3/ABL/SRC family kinases inhibitor |
| A3940 | XL388 | 1251156-08-7 | 98.00% | MTOR inhibitor,highly potent and selective |
| A3942 | XMD17-109 | 1435488-37-1 | 99.71% | ERK-5 inhibitor |
| A3943 | XMD8-92 | 1234480-50-2 | 98.18% | BMK1/ERK5 inhibitor |
| A3944 | X-NeuNAc | 160369-85-7 | 99.58% | Subtrate for chromogeneic assay of neuraminidase activity |
| A3946 | YK-4-279 | 1037184-44-3 | 99.72% | RNA Helicase A (RHA) inhibitor |
| A3947 | YM-155 hydrochloride | 355406-09-6 | 98.00% | Potent survivin inhibitor |
| A3950 | Zardaverine | 101975-10-4 | 98.00% | PDE III and IV inhibitor |
| A3952 | Ziprasidone | 146939-27-7 | 97.77% | 5-HT (serotonin)/dopamine receptor antagonist |
| A3953 | Ziprasidone hydrochloride monohydrate | 138982-67-9 | 98.30% | 5-HT (serotonin)/dopamine receptor antagonist |
| A3954 | ZM323881 | 193001-14-8 | 98.00% | VEGFR-2/KDR inhibitor,potent and selective |
| A3956 | Zosuquidar | 167354-41-8 | 98.49% | MDR modulator |
| A3958 | Veliparib dihydrochloride | 912445-05-7 | 98.56% | PARP-1/PARP-2 inhibitor |
| A3962 | AZD1208 | 1204144-28-4 | 99.82% | PIM kinase inhibitor |
| A3963 | A-769662 | 844499-71-4 | 97.68% | AMPK activator,potent and reversible |
| A3965 | BI 2536 | 755038-02-9 | 98.78% | Plk1 inhibitor,potent and ATP-competitive |
| A3966 | Doxorubicin | 23214-92-8 | 99.31% | Topo II inhibitor,immunosuppresive antineoplastic antibiotic |
| A3967 | Lapatinib Ditosylate | 388082-77-7 | 99.94% | EGFR/HER2 inhibitor,potent and selective |
| A3968 | PF-03716556 | 928774-43-0 | 98.00% | Acid pump antagonist,potent and selective |
| A3969 | Vatalanib | 212141-54-3 | 99.57% | VEGFR-1/-2 inhibitor,cell-permeable |
| A4002 | IU1 | 314245-33-5 | 99.00% | Usp14 inhibitor |
| A4003 | LDN 57444 | 668467-91-2 | 99.79% | UCH-L1 inhibitor,reversible competitve |
| A4004 | NSC 632839 hydrochloride | 157654-67-6 | 98.68% | Isopeptidases inhibitor |
| A4005 | RO4929097 | 847925-91-1 | 99.40% | γ secretase inhibitor |
| A4006 | MK-0752 | 471905-41-6 | 99.45% | γ-secretase inhibitor |
| A4007 | MLN9708 | 1201902-80-8 | 99.16% | Proteasome inhibitor |
| A4008 | MLN2238 | 1072833-77-2 | 98.00% | β5 site of the 20S proteasome inhibitor |
| A4009 | CEP-18770 | 847499-27-8 | 98.00% | Proteasome inhibitor |
| A4010 | Salinosporamide A (NPI-0052, Marizomib) | 437742-34-2 | ≥95.00% | 20S proteasome inhibitor |
| A4011 | ONX-0914 (PR-957) | 960374-59-8 | 95.30% | Immunoproteasome inhibitor,potent and selective |
| A4012 | Gabexate mesylate | 56974-61-9 | 99.41% | Trypsin-like serine proteinases inhibitor |
| A4013 | Aspirin (Acetylsalicylic acid) | 50-78-2 | 98.92% | Cyclooxygenase (COX) inhibitor |
| A4014 | Artemether (SM-224) | 71963-77-4 | 98.00% | Semi-synthetic derivative of artemisinin |
| A4015 | Disulfiram | 97-77-8 | 98.00% | Dopamine β-hydroxylase inhibitor |
| A4016 | Apoptosis Activator 2 | 79183-19-0 | 98.00% | Indoledione caspase activator, cell-permeable |
| A4018 | YO-01027 (Dibenzazepine, DBZ) | 209984-56-5 | 98.30% | γ-secretase inhibitor |
| A4019 | LY-411575 | 209984-57-6 | 98.21% | Gamma secretase inhibitor |
| A4020 | LY2811376 | 1194044-20-6 | 98.00% | Non-peptidic BACE1 inhibitor |
| A4022 | BMS-708163 (Avagacestat) | 1146699-66-2 | 98.73% | γ-secretase inhibitor |
| A4023 | LY3039478 | 1421438-81-4 | 97.16% | Notch inhibitor, novel and potent |
| A4024 | Danoprevir (RG7227) | 850876-88-9 | 98.47% | HCV NS3/4A protease inhibitor |
| A4031 | Telaprevir (VX-950) | 402957-28-2 | 98.00% | HCV NS3-4A protease inhibitor |
| A4032 | VX-222 (VCH-222, Lomibuvir) | 1026785-59-0 | 99.91% | NNI of HCV RNA polymerase |
| A4033 | Glimepiride | 93479-97-1 | 98.14% | Sulfonylurea compound |
| A4034 | Linagliptin (BI-1356) | 668270-12-0 | 99.69% | DDP-4 inhibitor,highly potent and competitive |
| A4036 | Sitagliptin phosphate monohydrate | 654671-77-9 | 98.19% | Potent DPP-4 inhibitor |
| A4037 | Vildagliptin (LAF-237) | 274901-16-5 | 98.05% | DPP-4 inhibitor |
| A4038 | Alogliptin (SYR-322) | 850649-61-5 | 97.66% | DPP-4 inhibitor,potent and highly selective |
| A4040 | Atazanavir sulfate (BMS-232632-05) | 229975-97-7 | 99.68% | Protease inhibitor |
| A4049 | Marimastat | 154039-60-8 | 98.00% | MMPs inhibitor,board spectrum |
| A4050 | GM 6001 | 142880-36-2 | 98.68% | Broad spectrum MMP inhibitor |
| A4051 | NSC 405020 | 7497-07-6 | 99.13% | MT1-MMP inhibitor |
| A4052 | Doxycycline hyclate | 24390-14-5 | 98.00% | MMP inhibitor |
| A4054 | 17-AAG (KOS953) | 75747-14-7 | 98.53% | Hsp90 inhibitor |
| A4056 | AT13387 | 912999-49-6 | 99.12% | Hsp90 inhibitor |
| A4057 | AUY922 (NVP-AUY922) | 747412-49-3 | 98.26% | Potent Hsp90 inhibitor |
| A4058 | BIIB021 | 848695-25-0 | 99.51% | Hsp90 inhibitor,selective and competitive |
| A4060 | Geldanamycin | 30562-34-6 | 97.01% | Hsp90 inhibitor,potent and specific |
| A4061 | IPI-504 (Retaspimycin hydrochloride) | 857402-63-2 | 98.20% | Hsp90 inhibitor,novel, potent,selective |
| A4062 | KW-2478 | 819812-04-9 | 98.00% | Potent Hsp90 inhibitor, novel, non-ansamycin, |
| A4063 | MPC-3100 | 958025-66-6 | 98.00% | Hsp90 inhibitor |
| A4064 | NVP-BEP800 | 847559-80-2 | 99.22% | Oral Hsp90β inhibitor, novel, fully synthetic |
| A4065 | PF-04929113 (SNX-5422) | 908115-27-5 | 99.61% | Hsp90 inhibitor,potent and selective |
| A4067 | Radicicol | 12772-57-5 | 98.00% | ATPase/kinase inhibitor |
| A4068 | SNX-2112 | 908112-43-6 | 98.00% | Hsp90 inhibitor,ATP-competitve,potent and selective |
| A4069 | BMS-707035 | 729607-74-3 | 99.68% | HIV-I integrase inhibitor,potent and specific |
| A4070 | Elvitegravir (GS-9137) | 697761-98-1 | 99.07% | HIV-1 integrase inhibitor,potent |
| A4071 | Fluorouracil (Adrucil) | 51-21-8 | 99.94% | Antitumor agent;inhibitor of thymidylate synthase |
| A4073 | Raltegravir (MK-0518) | 518048-05-0 | 99.73% | HIV-1 integrase inhibitor |
| A4074 | S/GSK1349572 | 1051375-16-6 | 99.89% | HIV integrase inhibitor, novel and potent |
| A4077 | BIBR 953 (Dabigatran, Pradaxa) | 211914-51-1 | 99.44% | Thrombin inhibitor,potent,reversible and direct |
| A4078 | Captopril | 62571-86-2 | 98.91% | ACE inhibitor |
| A4079 | Fosinopril sodium | 88889-14-9 | 98.00% | ACE inhibitor |
| A4080 | Moxonidine | 75438-57-2 | 99.53% | I1R/α2AR agonist |
| A4082 | Olmesartan medoxomil | 144689-63-4 | 99.38% | AT1 receptor antagonist |
| A4083 | Rocilinostat (ACY-1215) | 1316214-52-4 | 99.40% | Selective HDAC6 inhibitor |
| A4084 | Vorinostat (SAHA, MK0683) | 149647-78-9 | 99.89% | HDAC inhibitor |
| A4089 | Mocetinostat (MGCD0103, MG0103) | 726169-73-9 | 98.49% | HDAC inhibitor,isotype-selective and potent |
| A4090 | JNJ-26481585 | 875320-29-9 | 99.01% | Potent HDAC inhibitor |
| A4091 | PCI-34051 | 950762-95-5 | 98.67% | HDAC8 inhibitor,potent and selective |
| A4092 | CUDC-101 | 1012054-59-9 | 99.56% | Multitargeted HDAC inhibitor |
| A4093 | ITF2357 (Givinostat) | 732302-99-7 | 98.28% | HDAC inhibitor |
| A4094 | MC1568 | 852475-26-4 | 98.44% | Class II HDAC inhibitor,potent and selective |
| A4095 | Pracinostat (SB939) | 929016-96-6 | 98.89% | Pan-HDAC inhibitor |
| A4096 | Belinostat (PXD101) | 414864-00-9 | 98.04% | Hydroxamate-type HDAC inhibitor |
| A4097 | CUDC-907 | 1339928-25-4 | 98.06% | Potent PI3K/HDAC inhibitor |
| A4098 | PCI-24781 (CRA-024781) | 783355-60-2 | 98.01% | Pan-HDAC inhibitor |
| A4099 | Valproic acid sodium salt (Sodium valproate) | 1069-66-5 | 98.07% | HDAC inhibitor |
| A4100 | Droxinostat | 99873-43-5 | 98.00% | Selective HDAC inhibitor |
| A4101 | Tubastatin A | 1252003-15-8 | 98.00% | HDAC6 inhibitor,potent and selective |
| A4102 | CI994 (Tacedinaline) | 112522-64-2 | 98.17% | HDAC inhibitor |
| A4103 | LAQ824 (NVP-LAQ824,Dacinostat) | 404951-53-7 | 98.12% | HDAC inhibitor,potent and novel |
| A4104 | AR-42 (OSU-HDAC42) | 935881-37-1 | 99.03% | HDAC inhibitor,novel and potent |
| A4105 | M344 | 251456-60-7 | 98.73% | HDAC inhibitor,potent and cell-permeable |
| A4106 | Scriptaid | 287383-59-9 | 98.70% | HDAC inhibitor,novel and cell-permeable |
| A4107 | Sodium Phenylbutyrate | 1716-12-7 | 99.78% | Histone deacetylase inhibitor |
| A4108 | Resminostat (RAS2410) | 864814-88-0 | 98.00% | Potent HDAC inhibitor |
| A4110 | MLN8237 (Alisertib) | 1028486-01-2 | 98.77% | Aurora A Kinase inhibitor, Potent and selective |
| A4111 | VX-680 (MK-0457,Tozasertib) | 639089-54-6 | 99.93% | Aurora kinase inhibitor |
| A4112 | Barasertib (AZD1152-HQPA) | 722544-51-6 | 98.25% | Aurora Kinase B inhibitor, Potent and selective |
| A4113 | ZM 447439 | 331771-20-1 | 98.80% | Aurora Kinase inhibitor,potent and selective |
| A4114 | MLN8054 | 869363-13-3 | 97.64% | Aurora A inhibitor |
| A4115 | JNJ-7706621 | 443797-96-4 | 98.11% | Potent CDK/Aurora kinase inhibitor |
| A4116 | Danusertib (PHA-739358) | 827318-97-8 | 99.39% | Pan-aurora kinase inhibitor |
| A4117 | AT9283 | 896466-04-9 | 99.29% | Aurora kinase/JAK inhibitor |
| A4118 | Hesperadin | 422513-13-1 | 98.29% | Aurora B kinase inhibitor |
| A4119 | AMG-900 | 945595-80-2 | 98.99% | Aurora kinase inhibitor |
| A4120 | MK-5108 (VX-689) | 1010085-13-8 | 96.91% | Aurora-A kinase inhibitor,highly selective |
| A4121 | SNS-314 Mesylate | 1146618-41-8 | 99.94% | Aurora A/B/C kinases inhibitor, potent and selective |
| A4122 | PHA-680632 | 398493-79-3 | 98.53% | Aurora kinase inhibitor,novel and potent |
| A4123 | KW 2449 | 1000669-72-6 | 99.94% | Multikinase inhibitor |
| A4124 | TAK-901 | 934541-31-8 | 98.00% | Novel Aurora A/B inhibitor |
| A4125 | CYC116 | 693228-63-6 | 98.71% | Potent Aurora A/B inhibitor |
| A4126 | Aurora A Inhibitor I | 1158838-45-9 | 98.83% | Aurora A inhibitor |
| A4127 | GSK1070916 | 942918-07-2 | 98.00% | Aurora B/C inhibitor |
| A4128 | PF-03814735 | 942487-16-3 | 98.00% | Aurora A/B inhibitor |
| A4129 | ENMD-2076 L-(+)-Tartaric acid | 1291074-87-7 | 99.36% | Aurora kinases inhibitor |
| A4130 | ENMD-2076 | 934353-76-1 | 98.78% | Selective Aurora A/Flt3 inhibitor |
| A4132 | CCT137690 | 1095382-05-0 | 98.00% | Aurora A/B/C inhibitor |
| A4135 | Tofacitinib (CP-690550) Citrate | 540737-29-9 | 99.64% | Potent JAK inhibitor |
| A4136 | TG101348 (SAR302503) | 936091-26-8 | 99.39% | JAK-2 inhibitor,potent and selective |
| A4137 | AZD1480 | 935666-88-9 | 99.31% | JAK2 inhibitor,ATP-competitive and novel |
| A4138 | Tofacitinib (CP-690550,Tasocitinib) | 477600-75-2 | 99.94% | Janus kinase inhibitor |
| A4139 | AG-490 | 133550-30-8 | 99.76% | JAK2/EGFR inhibitor |
| A4140 | WP1066 | 857064-38-1 | 99.84% | JAK2/STAT3 inhibitor,cell-permeable |
| A4141 | Baricitinib (LY3009104, INCB028050) | 1187594-09-7 | 98.06% | JAK1/JAK2 inhibitor,selective orally bioavailable |
| A4143 | CYT387 | 1056634-68-4 | 98.70% | JAK-1/-2 inhibitor,ATP competitive |
| A4144 | AZ 960 | 905586-69-8 | 98.00% | JAKs inhibitor |
| A4145 | TG101209 | 936091-14-4 | 99.46% | JAK2/3 inhibitor |
| A4146 | CEP-33779 | 1257704-57-6 | 98.00% | JAK2 inhibitor,highly selective |
| A4147 | LY2784544 | 1229236-86-5 | 98.00% | JAK2 inhibitor,highly potent and selective |
| A4148 | NVP-BSK805 2HCl | 1092499-93-8 (free base) | 99.23% | JAK2 inhibitor |
| A4149 | S-Ruxolitinib (INCB018424) | 941685-37-6 | 99.34% | JAK1/2 inhibitor,potent and selective |
| A4150 | WHI-P154 | 211555-04-3 | 99.19% | JAK3 inhibitor |
| A4151 | ZM 39923 HCl | 1021868-92-7 | 99.91% | JAK3 inhibitor,potent and selective |
| A4152 | BMS-911543 | 1271022-90-2 | 98.41% | JAK2 inhibitor,selective small molecule |
| A4153 | BMN 673 | 1207456-01-6 | 99.26% | Potent PARP inhibitor |
| A4154 | Olaparib (AZD2281, Ku-0059436) | 763113-22-0 | 99.80% | Potent PARP1/PARP2 inhibitor |
| A4156 | Rucaparib (AG-014699,PF-01367338) | 459868-92-9 | 98.46% | Potent PARP inhibitor |
| A4157 | Iniparib (BSI-201) | 160003-66-7 | 99.08% | PARP1 inhibitor,intravenously adminsitered |
| A4158 | AG-14361 | 328543-09-5 | 99.17% | Potent PARP1 inhibitor |
| A4159 | PJ34 hydrochloride | 344458-15-7 | 99.54% | PARP inhibitor,potent and cell-permeable |
| A4160 | A-966492 | 934162-61-5 | 99.03% | PARP-1/-2 inhibitor, highly potent |
| A4161 | 3-aminobenzamide | 3544-24-9 | 99.66% | Potent PARP inhibitor |
| A4163 | UPF 1069 | 1048371-03-4 | 98.00% | Selective PARP2 inhibitor |
| A4164 | AZD2461 | 1174043-16-3 | 98.00% | Novel PARP inhibitor |
| A4166 | EPZ5676 | 1380288-87-8 | 99.28% | DOT1L inhibitor,potent and SAM competitive |
| A4167 | SGC 0946 | 1561178-17-3 | 99.65% | DOT1L inhibitor,highly potent and selective |
| A4168 | Entacapone | 130929-57-6 | 99.28% | COMT inhibitor |
| A4170 | EPZ004777 | 1338466-77-5 | 99.43% | DOT1L inhibitor |
| A4171 | EPZ005687 | 1396772-26-1 | 98.66% | EZH2 inhibitor,potent and selective |
| A4176 | Thioguanine | 154-42-7 | 98.18% | Purine antimetabolite |
| A4180 | SRT1720 HCl | 1001645-58-4 | 99.52% | SIRT1 activator |
| A4181 | EX 527 (SEN0014196) | 49843-98-3 | 99.71% | SIRT1 inhibitor |
| A4182 | Resveratrol | 501-36-0 | 99.94% | SIRT1 activator |
| A4183 | Sirtinol | 410536-97-9 | 98.00% | SIRT inhibitor |
| A4184 | PFI-1 (PF-6405761) | 1403764-72-6 | 97.20% | BET inhibitor |
| A4186 | Bromosporine | 1619994-69-2 | 98.00% | Bromodomain inhibitor,non-selective |
| A4187 | FG-4592 (ASP1517) | 808118-40-3 | 99.92% | HIF prolyl-hydroxylase inhibitor |
| A4188 | 2-Methoxyestradiol (2-MeOE2) | 362-07-2 | 99.00% | Apoptotic, antiproliferative and antiangiogenic agent |
| A4189 | IOX2(Glycine) | 931398-72-0 | 98.10% | HIF-1α prolyl hydroxylase-2 (PHD2) inhibitor |
| A4190 | GSK J4 HCl | 1373423-53-0(free base) | 98.00% | Inhibitor of H3K27 demethylase JMJD3,potent and cell-permeable |
| A4191 | GSK J1 | 1373422-53-7 | 99.50% | H3K27 demethylase JMJD3 inhibitor |
| A4192 | SGI-1776 free base | 1025065-69-3 | 99.19% | Pim kinase inhibitor,ATP-competitive |
| A4193 | SMI-4a | 438190-29-5 | 99.76% | Potent Pim inhibitor |
| A4194 | Obatoclax mesylate (GX15-070) | 803712-79-0 | 98.49% | Potent Bcl-2 inhibitor |
| A4199 | Sabutoclax | 1228108-65-3 | 98.00% | pan-Bcl-2 inhibitor |
| A4200 | Apogossypolone (ApoG2) | 886578-07-0 | 98.00% | Bcl-2 inhibitor,nonpeptidic small molecule |
| A4202 | RITA (NSC 652287) | 213261-59-7 | 99.53% | Mdm2-p53 interaction and p53 ubiquitination blocking |
| A4203 | Tenovin-1 | 380315-80-0 | 99.90% | SIRT2 inhibitor, activates p53 |
| A4204 | JNJ-26854165 (Serdemetan) | 881202-45-5 | 98.35% | P53 activator, blocking Mdm2-p53 interaction |
| A4206 | Pifithrin-α (PFTα) | 63208-82-2 | 98.16% | p53 inhibitor |
| A4208 | NSC 319726 | 71555-25-4 | 98.00% | Reactivator of mutant p53 |
| A4209 | NSC 207895 (XI-006) | 58131-57-0 | 98.00% | MDMX inhibitor,anti-cancer agent |
| A4210 | Bay 11-7821 (BAY 11-7082) | 19542-67-7 | 99.91% | IKK/NF-κB/TNFα inhibitor |
| A4211 | Lenalidomide (CC-5013) | 191732-72-6 | 98.66% | Antineoplastic agent,inhibits angiogenesis |
| A4212 | Pomalidomide (CC-4047) | 19171-19-8 | 98.46% | Immunomodulator,antumor/anti-angiogenic |
| A4213 | Necrostatin-1 | 4311-88-0 | 99.88% | RIP1 inhibitor |
| A4216 | Thalidomide | 50-35-1 | 99.21% | Immunomodulatory agent,sedative drug,angiogenesis inhibitor |
| A4217 | QNZ (EVP4593) | 545380-34-5 | 99.41% | Potent NF-κB inhibitor |
| A4219 | Birinapant (TL32711) | 1260251-31-7 | 98.13% | Potent XIAP/cIAP1 antagonist |
| A4221 | YM155 | 781661-94-7 | 99.60% | Survivin suppressant,apoptosis inhibitor |
| A4224 | GDC-0152 | 873652-48-3 | 99.00% | IAP antagonist,potent amd samll-molecule |
| A4227 | Tipifarnib (Zarnestra) | 192185-72-1 | 99.18% | Farnesyltransferase inhibitor,potent and specific |
| A4228 | Nutlin-3 | 890090-75-2 | 98.35% | MDM2 antagonist,inhibits MDM2-p53 interaction |
| A4230 | NSC 66811 | 6964-62-1 | 98.00% | MDM2 inhibitor |
| A4232 | Cyclophosphamide monohydrate | 6055-19-2 | 98.00% | alkylating, cytotoxic agent,antitumor activity |
| A4233 | Methylprednisolone | 83-43-2 | 99.31% | Apoptosis inducer,GR agonist |
| A4234 | TW-37 | 877877-35-5 | 98.13% | Bcl-2 inhibitor, inhibits Bcl-2,Bcl-XL and Mcl-1 |
| A4237 | Amuvatinib (MP-470, HPK 56) | 850879-09-3 | 99.91% | Tyrosine kinase inhibitor |
| A4240 | Abiraterone | 154229-19-3 | 99.30% | Potent CYP17 inhibitor |
| A4300 | GW9662 | 22978-25-2 | 99.25% | PPARγ antagonist |
| A4301 | T0070907 | 313516-66-4 | 99.88% | Human PPARγ antagonist,potent and selective |
| A4302 | Rosiglitazone maleate | 155141-29-0 | 99.15% | PPARγ agonist,high-affinity and selective,potent insulin sensitizer |
| A4303 | GSK3787 | 188591-46-0 | 99.73% | PPARβ/δ antagonist,novel and irreversible |
| A4304 | Rosiglitazone | 122320-73-4 | 99.80% | Potent PPARγ agonist |
| A4305 | WY-14643 (Pirinixic Acid) | 50892-23-4 | 99.87% | PPARα agonist,selective and highly potent |
| A4306 | Ciprofibrate | 52214-84-3 | 98.88% | PPARα agonist |
| A4307 | GW0742 | 317318-84-6 | 99.64% | PPARδ/β agonist,potent and selective |
| A4308 | Alizarin | 72-48-0 | 98.03% | Chelator for calcium,used to stain calcium deposites,Alizarin complexone is used for bone staining to study bone remodeling |
| A4309 | GW501516 | 317318-70-0 | 98.27% | PPARδ agonist,selective and potent |
| A4310 | Rosiglitazone HCl | 302543-62-0 | 99.31% | PPARγ agonist |
| A4311 | PF-4981517 | 1390637-82-7 | 98.00% | CYP3A4 inhibitor,potent and selective |
| A4313 | Cobicistat (GS-9350) | 1004316-88-4 | 99.94% | Selective CYP3A inhibitor |
| A4316 | Ketoconazole | 65277-42-1 | 99.48% | Inhibitor of cyclosporine oxidase and testosterone 6 beta-hydroxylase |
| A4317 | Apremilast (CC-10004) | 608141-41-9 | 98.98% | PDE4 inhibitor |
| A4318 | Avasimibe | 166518-60-1 | 99.66% | ACAT inhibitor,orally bioavailable |
| A4319 | Roflumilast | 162401-32-3 | 99.08% | PDE-4 inhibitor |
| A4320 | Voriconazole | 137234-62-9 | 99.96% | CYP51 inhibitor |
| A4321 | Sildenafil Citrate | 171599-83-0 | 99.63% | Treat erectile dysfunction and PAH |
| A4322 | Clarithromycin | 81103-11-9 | 99.39% | CYP3A inhibitor, potent |
| A4323 | Vardenafil HCl Trihydrate | 330808-88-3 | 99.63% | PDE5 inhibitor, potent and selective |